Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven T Harris

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
The Journal of Rheumatology|October 6, 2005
Safety and tolerability of oral daily and intermittent ibandronate are not influenced by ageMark P Ettinger, Dieter Felsenberg, Steven T Harris, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|December 13, 2017
Proceedings of the 2017 Santa Fe Bone Symposium: Insights and Emerging Concepts in the Management of OsteoporosisE Michael Lewiecki, John P Bilezikian, John J Carey, et al.
The American Journal of Medicine|November 27, 2012
Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holidayMichael McClung, Steven T Harris, Paul D Miller, et al.
Bone|January 9, 2020
History of etidronateNelson B Watts, Charles H Chesnut, Harry K Genant, et al.
Current Medical Research and Opinion|April 7, 2005
Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONECharles H Chesnut, Mark P Ettinger, Paul D Miller, et al.
The American Journal of Medicine|October 27, 2009
Assessing fracture risk and effects of osteoporosis drugs: bone mineral density and beyondK Shawn Davison, David L Kendler, Patrick Ammann, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 13, 2011
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosisNelson B Watts, John P Bilezikian, Pauline M Camacho, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 11, 2011
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendationsNelson B Watts, John P Bilezikian, Pauline M Camacho, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 2, 2005
Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) studyEthel S Siris, Steven T Harris, Richard Eastell, et al.
Endocrine Reviews|March 17, 2005
Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its useAnthony B Hodsman, Douglas C Bauer, David W Dempster, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
The Journal of Rheumatology|October 6, 2005
Safety and tolerability of oral daily and intermittent ibandronate are not influenced by ageMark P Ettinger, Dieter Felsenberg, Steven T Harris, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|December 13, 2017
Proceedings of the 2017 Santa Fe Bone Symposium: Insights and Emerging Concepts in the Management of OsteoporosisE Michael Lewiecki, John P Bilezikian, John J Carey, et al.
The American Journal of Medicine|November 27, 2012
Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holidayMichael McClung, Steven T Harris, Paul D Miller, et al.
Bone|January 9, 2020
History of etidronateNelson B Watts, Charles H Chesnut, Harry K Genant, et al.
Current Medical Research and Opinion|April 7, 2005
Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONECharles H Chesnut, Mark P Ettinger, Paul D Miller, et al.
The American Journal of Medicine|October 27, 2009
Assessing fracture risk and effects of osteoporosis drugs: bone mineral density and beyondK Shawn Davison, David L Kendler, Patrick Ammann, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 13, 2011
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosisNelson B Watts, John P Bilezikian, Pauline M Camacho, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 11, 2011
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendationsNelson B Watts, John P Bilezikian, Pauline M Camacho, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 2, 2005
Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) studyEthel S Siris, Steven T Harris, Richard Eastell, et al.
Endocrine Reviews|March 17, 2005
Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its useAnthony B Hodsman, Douglas C Bauer, David W Dempster, et al.
Pageof 4